CTX Captor Therapeutics Spolka Akcyjna
Captor Therapeutics Spolka Akcyjna, a biopharmaceutical company, develops therapeutic molecules for treating oncological and autoimmune diseases in Poland. The company offers targeted protein degradation technology that utilizes the Optigrade drug discovery platform to overcome the limitations of inhibitors and antibody drugs by destroying disease-causing proteins that are resistant to available therapeutics. It develops viadrudomide, which is in a Phase 1 clinical trial for hepatocellular carcinoma (HCC), lung cancer, and rare cancers; vratitoclax, a bifunctional MCL-1 protein degrader that is in the CTA-enabling stage for liquid and solid tumors; CT-02B, a NEK7 degrader that is in preclinical trials for neuroinflammation indications in Parkinson's disease, amyotrophic lateral sclerosis (ALS), and multiple sclerosis (MS); CT-02S, a NEK7 degrader that is in preclinical trials for systemic autoimmunity indications in inflammatory bowel diseases (IBD), gout, and dermatological diseases; and CT-05, a PKCtheta degrader that is in preclinical trials for autoimmunity, transplantation, and metabolism indications. In addition, the company's candidates in the discovery phase include an undisclosed project for oncology, autoimmunity, CNS, and rare indications; and novel E3 ligases for oncology and autoimmunity indications. Captor Therapeutics Spolka Akcyjna was incorporated in 2015 and is headquartered in Wroclaw, Poland.…
Industry Peers
BiotechnologyKey Statistics
About Captor Therapeutics Spolka Akcyjna (WSE: CTX)
›
Captor Therapeutics Spolka Akcyjna (WSE: CTX) is listed on Warsaw Stock Exchange, where its shares trade in PLN. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 82 employees.
The shares were at 52.20 PLN on 19 November 2026, up 18.4% over 52 weeks. Its 52-week range is 44.80 PLN to 89.20 PLN: the price is 41.5% below the high and 16.5% above the low.
Its market capitalisation is 330.60M PLN.
Captor Therapeutics Spolka Akcyjna reports return on equity of -178.9% and revenue down 18.7% year over year.
It holds more cash than debt, a net cash position of 68.84M PLN. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 3 analysts cover the stock; their mean price target of 91.90 PLN is 76.1% above the current price.